NCT03801369: Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who are BRCA+, Participants with known active unstable central nervous system (CNS) metastases that require steroids and/or carcinomatous meningitis- see trial for details

Comments are closed.

Up ↑